29 Sep 11
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights:
17 Aug 11
For recent graduates from science, medicine, or mathematics programs, applying for work in the ever-expanding pharmaceutical industry can be an intelligent choice for both career and financial stability. Depending on the industry upon which you choose to focus, the rules and expectations during the interview process can vary.
17 Aug 11
Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter
27 Jun 11
At a moment when the national discourse on international aid is grounded in pessimism, David Cameron’s pledge to commit £814m to help vaccinate the world’s poorest children provides an necessary reminder of what international aid really can achieve.
31 May 11
Certolizumab pegol (Cimzia ®) delivered rapid and consistent improvements in a broad range of rheumatoid arthritis (RA) patients after 12 weeks of treatment regardless of whether or not they had received prior TNF inhibitors or whether or not they were receiving concomitant DMARDs, concluded the latest analysis of the Phase III b REALISTIC trial presented at the European League Against Rheumatism (EULAR) meeting in London, May 25-28 (abstract FRI021).
24 Feb 11
After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter
07 Feb 11
If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting.
However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
29 Sep 10
There has been some conjecture amongst professionals regarding the merits of a personal profile on a CV. This conjecture stems from the fact that many job seekers fill there personal profiles with irrelevant and mostly clichéd information.
20 May 10
Economic uncertainty has fueled a growing trend toward self-employment and entrepreneurialism with one-in-five respondents worldwide now working outside the traditional employment relationship, and 50 percent saying that they would like to do so, according to the latest survey results from workforce solutions leader Kelly Services®.
27 Jan 10
RSS is a much under-estimated and under-used thing. It was originally conceived as an easy way of syndicating website content, hence the name “Really Simple Syndication”, but it now become a standard by which content is made available across the web to other sites or users.
14 Jan 10
Washington is famous for its lobbyists. Make no mistake, of all the industries currently making themselves heard on Capitol Hill, the healthcare lobby is one of the largest and the loudest. Indeed, according to the Center for Responsive Politics, the pharmaceutical industry had almost 1700 registered lobbyists in Washington as of late 2009. Unsurprisingly, then, the pharmaceutical industry has a considerable degree of pull on The Hill.
08 Dec 09
‘You really need some more experience’. Perhaps the most ubiquitous phrase in modern day recruitment, thousands of graduates are now at the mercy of this one requirement as increasing competition in the job market leads to rising standards. Perhaps twenty, or even ten years ago, an undergraduate degree and a forceful sense of charisma might well have been enough to net you your first role in an industry.
08 Dec 09
Keynes called it an ‘inducement to invest’. In this instance, the most recent financial crisis has called for many of the same approaches used in the 1930s to stimulate the economy and bring industries back to their feet. Today more than ever, we realize that education is one of the most decisive facets of any successful stimulus.
08 Dec 09
At what point does a conflict of interests occur? Last year – and for many years before that – U.S. drugs companies paid out tens of millions of dollars in payments and gifts to physicians and academics. Earlier this year, the Pharmaceutical and Research Manufacturers of America (PhRMA) released a revised, and somewhat toughened, code of practice.
26 Nov 09
I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
17 Nov 09
We're having a fascinating day at the Financial Times Global Pharmaceutical and Biotechnology conference on London.
30 Sep 09
It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
25 Sep 09
With the pharmaceutical industry heading into the well documented “expiry cliff” competition is rife. Quicker more cost effective methods of manufacturing must be found for big pharma to remain competitive and a clearer means of communication such as that seen at the NG Pharma Summit is clearly vital.
NG Online News
16 Sep 09
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.